Alkem Lab — Q3 FY25 earnings call

Call held 7 Feb 2025

Management summary

Alkem Lab reported a resilient Q3 FY25 with modest revenue growth and strong EBITDA margin expansion, driven by improved profitability actions and domestic market performance. The company is strategically expanding its portfolio through acquisitions and preparing for key product launches like GLP-1 in India. While facing challenges in the US market due to price erosion and specific non-US markets like Chile, management remains confident in achieving its full-year EBITDA margin guidance and future growth drivers.

Highlights

  • Revenue from operations for Q3 FY25 was INR33,743 million, with a 1.5% YoY growth.

  • Q3 FY25 EBITDA was INR7,594 million, resulting in a margin of 22.5%, an increase of 7.3% YoY.

  • Net profit for Q3 FY25 was INR6,258 million, growing 5.2% YoY.

  • Domestic market growth was 6% YoY, against a market growth of 7.2%, and outperformed the acute market's 5.7% growth.

  • The company is on track to be among the first players to launch GLP-1 (semaglutide) in India.

  • Net cash position is strong at around INR4,700 crores with zero leverage.

Concerns

  • The US market experienced price erosion of around 5% in Q3 FY25.

  • Non-US markets, particularly Chile, saw significant degrowth (almost 30%) due to tender issues and currency depreciation.

  • Trade generics business has seen some sluggishness due to increased competition and pricing pressure, though management aims for high single-digit growth.

  • Q4 FY25 EBITDA margin is expected to see a slight contraction due to higher R&D spend and additional filings.

Key financials

  1. Revenue from Operations 33,743 Mn +1.5%YoY
  2. EBITDA 7,594 Mn +7.3%YoY
  3. EBITDA Margin 22.5%
  4. Net Profit 6,258 Mn +5.2%YoY
  5. Trade Generics Revenue 4,880 Mn
  6. NLEM Portfolio % of Sales 30%

What they filed

Q1 FY27: revenue up 10.9%, net profit down 22.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue3,415 3,374 3,144 3,371 4,001 +17%3,737 +11%3,603 +15%3,740 +11%
EBITDA753 759 391 739 921 +22%828 +9%517 +32%766 +4%
Net profit702 641 322 668 779 +11%653 +2%251 −22%521 −22%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Debt Net ₹4,700 Cr
    So we don't have any loans in our books. The net cash position is around INR4,700 crores.
  • M&A Adroit Acquisition · Announced · Consideration ₹[object Object] (cash)

    Pharmaceutical health care company with a focus on dermato-cosmetology, expanding presence in flagship brands and strategically enhancing portfolio.

    We have also announced 2 acquisitions, Adroit, the pharmaceutical health care company with a focus on dermato-cosmetology, at a cash consideration of INR140 crores.
  • M&A Bombay Ortho Acquisition · Announced · Consideration ₹[object Object] (cash)

    Manufacturer and supplier of automatic implants such as hip and knee implants, extensively used in orthopaedic fields. Capitalizes on growth in the value segment of medical devices and provides manufacturing capability.

    Provides manufacturing capability for around 2,000 hip and knee replacements monthly, reducing cost of production and aiming for good market share over 5 years in the value segment.

    And second is Bombay Ortho, a manufacturer and supplier of automatic implants such as hip and knee implants, which are extensively used in orthopaedic fields at a cash consideration of INR147 crores. ... So, I have seen that you have acquired it for around INR147 crores, which transfer turnover is around INR5 crores.
  • Liquidity Cash ₹4,700 Cr Company has zero leverage and a strong net cash position.
    So we don't have any loans in our books. The net cash position is around INR4,700 crores.

Guidance & targets

Margin

  • EBITDA Margin Margin · FY25 · High confidence around 19%
    So on the overall margins, I would say we are pretty much on track with the guidance that we gave earlier. Saion, as you know, Q4 is our lowest quarter, and we have a lot of filings that we are going to do in Q4, because of which our spending is also higher in Q4. So Q4 generally is sluggish, whatever, but our estimates are that we should be around 19%, with no guidance. We continue with our that guidance.

    — Vikas Gupta

Domestic Market

  • Domestic Growth Domestic Market · FY25 · High confidence around 7%
    The market is growing at around 7%. We should be pretty much in line with that kind of growth as far as India is concerned.

    — Vikas Gupta

  • Domestic Growth Domestic Market · Q4 FY25 · Medium confidence even stronger growth
    So, going forward, I would say, in fact, that in Q4, we are expecting even stronger growth as far as our domestic portfolio is concerned.

    — Vikas Gupta

International Business

  • US Market Performance International Business · Q4 FY25 · Medium confidence flat
    So if you look at even for Q4, we are expecting it to be, say, flat because as we are moving ahead from a minus 22%, we are at minus 7%. My sense is that by Q4, we should be neutral as compared to last year.

    — Vikas Gupta

  • US Market Price Erosion International Business · next year · High confidence mid-single-digit
    We look at price erosion at mid-single-digit kind of price erosion that -- and we expect that to continue even next year.

    — Vikas Gupta

  • Non-US Growth International Business · going forward · High confidence 13% to 14%
    And overall, I think for the non-U.S., I think we have given a guidance of 13% to 14% of growth going forward.

    — Nitin Agrawal

Product Pipeline

  • US Product Launches Product Pipeline · next year · High confidence 1 or 2 products
    Yes. So, there are 1 or 2 products like varenicline, and we are doing pretty well over there. Product launches will be 1 or 2, but because of a better supply situation now, which we had -- our stocks in the U.S. have come down to very low levels.

    — Vikas Gupta

  • Filings Product Pipeline · Q4 FY25 · High confidence 5 filings
    We are looking at least 5 filings in Q4.

    — Vikas Gupta

R&D

  • R&D Spend as % of Sales R&D · High confidence around 4.5% to 5%
    We're looking at around 4.5% to 5%, somewhere in that range.

    — Vikas Gupta

MedTech

  • MedTech Investment MedTech · next 3 or 4 years · High confidence not go beyond INR2,000 crores to INR2,500 crores
    See, on MedTech, maybe over the next 3 or 4 years, we may not go beyond INR2,000 crores to INR2,400 crores or INR2,500 crores of investment. That is what the plan is: a max of INR2,500 crores.

    — Nitin Agrawal

Trade Generics

  • Trade Generics Growth Trade Generics · coming years · Medium confidence high single-digit
    But yes, somewhere, a high single-digit kind of outlook is what I will have for a mid-to-high single-digit growth outlook is what we will have for this business.

    — Vikas Gupta

Enzene

  • Enzene Pune Growth Enzene · next year · High confidence around 15% to 20%
    So we can assume growth of around 15% to 20% in next year from the Pune unit.

    — Nitin Agrawal

What to watch in Q4 FY25

Q4 FY25 EBITDA Margin

Q4 FY25
Current 22.5% (Q3 FY25)
Target Slight contraction, but full-year 19% guidance maintained

Why it matters

To assess the impact of higher Q4 expenses and R&D spend on profitability and verify if the full-year EBITDA guidance of 19% is met.

So Q4 generally is sluggish, whatever, but our estimates are that we should be around 19%, with no guidance. We continue with our that guidance. ... See, there may be a slight contraction, but while we will try, we are still in the quarter.

Risks & concerns

  • US market price erosion

    medium

    Price erosion in the US market is around 5% and is expected to continue next year, though volume growth and new launches should offset it.

    Management acknowledged

  • Non-US market degrowth (Chile)

    medium

    Chile experienced almost 30% degrowth due to tender issues and currency depreciation, impacting overall non-US performance.

    Management acknowledged

  • Trade generics market competition and pricing pressure

    medium

    The trade generics business faces pressure from new players and competition, leading to some sluggishness, though the company focuses on maintaining margins.

    Management acknowledged

  • Higher expenses in Q4 FY25

    low

    Q4 is typically the lowest quarter with higher spending due to additional filings and R&D, which may lead to a slight contraction in EBITDA margin.

    Management acknowledged

  • PenG price increase

    low

    PenG prices have increased by 20-25% in the last two months, but current inventory levels mitigate immediate impact; long-term impact depends on stabilization.

    Analyst acknowledged

Q&A highlights

7 direct
Overhead expenses and FY25 EBITDA margin guidance Partial
So on the overall margins, I would say we are pretty much on track with the guidance that we gave earlier. Saion, as you know, Q4 is our lowest quarter, and we have a lot of filings that we are going to do in Q4, because of which our spending is also higher in Q4. So Q4 generally is sluggish, whatever, but our estimates are that we should be around 19%, with no guidance.

Analyst questioned the feasibility of the 19% EBITDA margin guidance given 9M performance and expected Q4 overheads, leading to management reiterating the guidance but acknowledging Q4 expenses.

Asked by Saion Mukherjee

US product launches (sacubitril-valsartan) and GLP-1 strategy in India Direct
So, first, on the GLP-1, we should be amongst the first wave of players who would come in with GLP-1. We have already represented ourselves to the regulator in India. And I think we are pretty much on track to be amongst the first few players who will come up with semaglutide in India at the time of launch. ... In the U.S., we have got approval for sacubitril-valsartan, that market -- that product is under -- I think there's a it's a matter of subjudice. So the market should open up by July.

Provides clarity on the company's strategy and timeline for entering the high-potential GLP-1 market in India and a key US product launch.

Asked by Saion Mukherjee

India growth, acute therapies slowdown, and GLP-1 manufacturing strategy Direct
See, our growth in India, even in this quarter, has been reported around 6%. If you see, the branded generic growth is even more is even stronger at around 7.5%-or-so, right? ... With regards to semaglutide, I think we are fully prepared. I cannot divulge where we will manufacture or what we will do. But I can tell you, we are fully prepared with our strategy to get to the market. So it's a product which our R&D has developed, and we will be launching it -- I will say we will be first amongst equal.

Addresses concerns about domestic market growth and provides insight into the company's preparedness for the GLP-1 launch, emphasizing in-house R&D.

Asked by Kunal Dhamesha

US market Q-o-Q improvement and price erosion Direct
Yes, price erosion is to the tune of around 5%, though on the NRV basis, because we had some forex gains because of the dollar, it's 2.5%. But if you look at its backed by more of our supply getting regularized. ... So I can say that because of our improved supply that we have -- it's not backed by any new launches that we have done in the U.S. It's just that some of the contracts that we had got out of, some of the accounts that we had got out of, we have again slowly and slowly getting back.

Explains the reasons for improved US performance (supply regularization) despite ongoing price erosion and clarifies that it's not due to new launches.

Asked by Rashmi Shetty

Rationale and market size for Bombay Ortho acquisition Direct
Bombay Ortho, we have acquired to actually capitalize on the growth in the value segment because the value segment in medical devices is growing at a very fast pace, and we wanted to capture it. And so this particular acquisition give us a manufacturing capability also because we didn't have any manufacturing setup for our ortho business. This will give us a capacity of around 2,000 hip and knee replacements, which can be manufactured on a monthly basis, and will allow us to reduce our cost of production of these instruments further or these implants further so that we can capture a good market share over the next 5 years in the value segment of ortho, hip and knee replacement.

Details the strategic rationale behind the Bombay Ortho acquisition, highlighting manufacturing capability, market segment focus, and cost reduction benefits.

Asked by Amlan Das

Capital allocation for larger acquisitions, especially in MedTech Direct
So, we've always said -- we've clearly defined our focus areas, right? Our first priority would be anything that we get in the India formulation business. ... Of course, MedTech, we have just made 1 small, I would say, acquisition. But going forward, also, it's an area of priority for us. If there is anything that comes at the right value, we would definitely consider it. ... on MedTech, maybe over the next 3 or 4 years, we may not go beyond INR2,000 crores to INR2,400 crores or INR2,500 crores of investment.

Clarifies the company's M&A strategy, prioritizing India formulations but also considering MedTech, and provides a long-term investment cap for MedTech.

Asked by Neha Manpuria

Reasons for non-US degrowth, specifically in Chile Direct
It's largely from one of our large markets, which is Chile. In Chile, we have 2 issues: one is some tenders that we came out of, and the second is the exchange rate. So the currency actually played spoilsport over there. So because of that, Chile, which is our one of the largest non-U.S. markets that has shown almost 30% degrowth, which is where our overall non-U.S. growth is looking sluggish.

Identifies specific external factors (tenders, currency depreciation) impacting performance in a key non-US market, explaining the overall non-US degrowth.

Asked by Foram Parekh

Divestment of Pithampur unit and potential cost optimization benefits Direct
So we have entered into an agreement for selling off the Indore, Pithampura unit because, see, for the last 4, 5 years, we've not been using it. So, strategically, it was not making sense for us to retain that unit, and it was a kind of inoperative asset. ... So I don't see any impact on our operations because of this sale because there were no sales happening from this unit for the last 3 or 4 years.

Explains the rationale for divesting an unused asset, indicating it's a strategic move with no operational impact, and clarifies that cost optimization benefits would be minimal as it was an inoperative asset.

Asked by Shrikant

3 min read 7 chapters

Detailed narrative

Q3 FY25 Financial Performance Overview

Alkem Laboratories reported Q3 FY25 revenue from operations of INR33,743 million, marking a 1.5% year-on-year growth. For the nine-month period, revenue stood at INR98,208 million, growing 0.9% YoY. The company achieved a Q3 EBITDA of INR7,594 million, translating to a robust 22.5% margin, which is a 7.3% increase YoY. Net profit for the quarter was INR6,258 million, up 5.2% YoY, and for the nine months, it reached INR18,596 million, a 23.8% YoY growth.

Domestic Market Performance & Strategy

The domestic market registered a 6% year-on-year growth in Q3 FY25, against a market growth of 7.2% as per IQVIA. The company's performance was at par or slightly better than the acute market, which grew 5.7%. Branded generic growth was even stronger at approximately 7.5%. Alkem's volume growth in India was 1.1%, surpassing the market's 0.3%. The company's strategy focuses on expanding flagship brands and enhancing its portfolio, with 7 therapies showing outperformance and 32 brands increasing market share.

International Business (US & ROW) Update

The US market experienced price erosion of around 5% in Q3 FY25, though the net revenue value impact was 2.5% due to forex gains. The US business showed a -7% degrowth in Q3, an improvement from -22% in Q2, primarily due to regularization of supply rather than new launches. For Q4, the US market is expected to be flat, with 1-2 new product launches anticipated next year. Non-US markets, particularly Chile, faced significant challenges with almost 30% degrowth due to tender issues and currency depreciation, impacting overall non-US growth, which is guided to be 13-14% going forward.

Strategic Acquisitions & Investments

Alkem announced two acquisitions: Adroit, a dermato-cosmetology focused pharmaceutical company, for INR140 crores, and Bombay Ortho, an orthopedic implant manufacturer, for INR147 crores. The Bombay Ortho acquisition aims to capitalize on the fast-growing value segment of medical devices and provides in-house manufacturing capabilities for hip and knee implants. Additionally, the company had an in-licensing deal for Exactech technology for around INR133 crores. Total MedTech investment is projected not to exceed INR2,000-2,500 crores over the next 3-4 years.

Margins & Cost Management

The company's focus on higher-margin offerings, market alignment, and cost-saving strategies has led to growth in EBITDA margins, reaching 22.5% in Q3 FY25. Management reiterated its full-year FY25 EBITDA margin guidance of around 19%. However, Q4 is typically the lowest quarter with higher expenses due to additional filings and R&D, which may lead to a slight contraction in the Q4 EBITDA margin. R&D spend is expected to be around 4.5% to 5% of sales.

Product Pipeline & Future Growth Drivers

Alkem is actively pursuing new product opportunities, notably in the GLP-1 (semaglutide) segment for India, aiming to be among the first wave of players to launch. The company has already represented itself to the regulator and is fully prepared with its R&D-developed product. In the US, approval for sacubitril-valsartan is expected to open up by July. The company plans for 5 filings in Q4 FY25, primarily generic in nature, and expects 1-2 US product launches next year.

Capital Allocation & Liquidity

Alkem maintains a strong financial position with zero leverage and a net cash position of approximately INR4,700 crores. The company's capital allocation strategy prioritizes India formulation business acquisitions but also considers MedTech opportunities if they offer value. The divestment of the inoperative Pithampur unit, which had not been used for 3-4 years, is expected to have no operational impact and minimal cost optimization benefits, mainly related to depreciation.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls